Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H30N2O2 |
| Molecular Weight | 354.4858 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=C(CC(O)=O)C(C2=CC=C(C)C=C2)=C(CN)C(CC(C)(C)C)=N1
InChI
InChIKey=HQVOROHHYWZJLD-UHFFFAOYSA-N
InChI=1S/C22H30N2O2/c1-6-18-16(11-20(25)26)21(15-9-7-14(2)8-10-15)17(13-23)19(24-18)12-22(3,4)5/h7-10H,6,11-13,23H2,1-5H3,(H,25,26)
| Molecular Formula | C22H30N2O2 |
| Molecular Weight | 354.4858 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:56:20 GMT 2025
by
admin
on
Tue Apr 01 16:56:20 GMT 2025
|
| Record UNII |
6TEM3HH2EG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11996845
Created by
admin on Tue Apr 01 16:56:20 GMT 2025 , Edited by admin on Tue Apr 01 16:56:20 GMT 2025
|
PRIMARY | |||
|
6TEM3HH2EG
Created by
admin on Tue Apr 01 16:56:20 GMT 2025 , Edited by admin on Tue Apr 01 16:56:20 GMT 2025
|
PRIMARY | |||
|
907609-33-0
Created by
admin on Tue Apr 01 16:56:20 GMT 2025 , Edited by admin on Tue Apr 01 16:56:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Inhibition of dipeptidyl peptidase IV (DPP-4) is an exciting new approach for the treatment of diabetes. After further optimization, we identified a hydrate of (5-(aminomethyl)-6-(2,2-dimethylpropyl)-2-ethyl-4-(4-methylphenyl)pyridin-3-yl)acetic acid (30c) as a potent and selective DPP-4 inhibitor. The desired interactions with the critical active-site residues, such as a salt-bridge interaction with Arg125, were confirmed by X-ray cocrystal structure analysis. In addition, compound 30c showed a desired preclinical safety profile, and it was encoded as TAK-100.
30c (TAK-100) Data for inhibition of dipeptidyl peptidase IV (DPP-4): IC50-PP-4a = 5.3(5.1-5.4)nM, IC50-DPP-2b = >100000nM, IC50-DPP-8c = >100000nM, IC50-DPP-9d = 60000(48000-79000)nM
|
||
|
ACTIVE MOIETY |
Originator: Takeda; Class: Antihyperglycaemic; Mechanism of Action: CD26 antigen inhibitor; Highest Development Phase: Discontinued for Type 2 diabetes mellitus; Most Recent Events: 21 May 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in Japan (PO), 06 May 2010 TAK 100 is still in phase I trials for Type-2 diabetes in Japan, 31 Jan 2008 Phase-I clinical trials in Type-2 diabetes mellitus in Japan (PO)
|
